文献速递瓣膜外科先天性心脏病外科

Ross术后肺动脉同种移植物长达25年的长期性能

Long-term performance of pulmonary homografts after the Ross procedure: experience up to 25 years.
PubMed 文献 · Eur J Cardiothorac Surg · 2019-01-01

该单中心回顾性研究纳入1991至2014年间接受Ross手术的274例患者,评估肺动脉同种移植物重建右室流出道的长期耐久性与功能。中位随访13.3年,10、15、20年免于移植物再干预率分别为95.6%、90.4%、87.5%,儿童再干预率显著更高,所有再干预患者均为男性。结论认为肺动脉同种移植物长期结果满意,性能差异与尺寸偏小和年轻年龄相关。

要点

  • Ross术后肺动脉同种移植物10、15、20年免于再干预率分别为95.6%、90.4%、87.5%。
  • 儿童患者免于再干预率显著低于成人(log-rank P < 0.001)。
  • 所有再干预患者均为男性(log-rank P = 0.009),女性移植物指数直径更大。

核心结论

  • 肺动脉同种移植物在Ross术后提供非常满意的长期结果。
  • 长期性能差异与移植物尺寸偏小和年轻年龄相关。

研究设计与样本

  • 单中心回顾性研究,纳入1991至2014年间接受Ross手术的274例患者(男212例,女62例,年龄3-59岁)。
  • 评估同种移植物相关并发症和再干预,并通过单一日照心脏病专家行经胸超声心动图测定血流动力学功能。

主要发现

  • 全因30天死亡率为1.1%(3例),另有17例晚期死亡,其中1例与同种移植物相关并发症有关。
  • 观察期间(中位13.3年;累计3327.5患者年),21例(7.7%)患者至少接受1次右室流出道再干预。
  • 10、15、20年免于同种移植物再干预率分别为95.6%、90.4%、87.5%。
  • 儿童患者免于再干预率显著更低(log-rank P < 0.001),所有再干预患者均为男性(log-rank P = 0.009)。
  • 女性患者接受的同种移植物指数直径显著大于男性(P < 0.001),可能与女性无再干预相关。

关键数值与推荐

  • 同种移植物心内膜炎线性发生率为0.2%/患者年。
  • 最近一次超声心动图(中位随访14.7年;164例患者)显示,150例(91.5%)跨同种移植物峰值压力梯度<40 mmHg。
  • 同种移植物反流程度:无或微量111例(67.7%),轻度49例(29.9%),中度3例(1.8%),1例(0.6%)无法确定。
  • 年轻患者年龄(P < 0.001)、较小的同种移植物直径(P = 0.014)和随访期间体表面积增加(P = 0.006)与更高的跨同种移植物峰值压力梯度显著相关。
  • 男性跨同种移植物峰值压力梯度显著高于女性(P = 0.018)。

临床怎么用

  • Ross术后应长期监测肺动脉同种移植物功能,尤其关注儿童和男性患者。
  • 选择同种移植物时需考虑尺寸匹配,避免尺寸偏小,以降低再干预风险。

局限性

  • 单中心回顾性研究,结果可能受选择偏倚影响。
  • 超声心动图随访仅由单一心脏病专家完成,且部分患者失访(最近超声仅164例)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to evaluate the long-term durability and function of pulmonary homografts used for right ventricular outflow tract reconstruction in the Ross procedure at a single centre with 25 years of experience. METHODS: The study included 274 patients (212 male patients and 62 female patients; age 3-59 years), who underwent the Ross procedure between 1991 and 2014. Homograft-related complications and reinterventions were assessed. Homograft haemodynamic function was determined using transthoracic echocardiography undertaken by a single cardiologist. RESULTS: The all-cause 30-day mortality was 1.1% (3 patients), and there were 17 late deaths. One death was associated with a homograft-related complication. During the observation period (median 13.3 years; 3327.5 cumulative patient-years), 21 patients (7.7%) underwent at least 1 right ventricular outflow tract reintervention. Freedom from homograft reintervention was 95.6%, 90.4% and 87.5% at 10, 15 and 20 years, respectively. Paediatric patients had a significant lower rate of freedom from reintervention (log-rank P < 0.001). Remarkably, all patients who underwent reintervention were male (log-rank P = 0.009). Female patients received homografts with a significantly higher (P < 0.001) indexed diameter than male patients, which might be causally related to absent reinterventions in women. The linearized rate of homograft endocarditis was 0.2% per patient-year. At the latest echocardiography (median follow-up time 14.7 years; 164 patients), the peak transhomograft pressure gradient was <40 mmHg in 150 patients (91.5%), and homograft incompetence was none or trivial in 111 patients (67.7%), mild in 49 patients (29.9%) and moderate in 3 patients (1.8%). In 1 patient (0.6%), it was not possible to determine the degree of incompetence. Younger patient age (P < 0.001), a smaller homograft diameter (P = 0.014) and an increase in the body surface area during the follow-up time (P = 0.006) were significantly correlated with a higher peak transhomograft pressure gradient. Men had a significantly higher peak transhomograft pressure gradient than women (P = 0.018). CONCLUSIONS: Pulmonary homografts provide very satisfying long-term results after the Ross procedure. Differences in long-term performance are related to undersizing and young age.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Oeser C, Uyanik-Uenal K, Kocher A, et al. Long-term performance of pulmonary homografts after the Ross procedure: experience up to 25 years. Eur J Cardiothorac Surg. 2019. PMID: 30476036. doi:10.1093/ejcts/ezy372

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。